Go Deep
Zeria Pharmaceutical Co., Ltd.
Zeria Pharmaceutical Co., Ltd. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 22,352 | 10.6 | 0.81 | 0.34 | 1,199.23 |
Zeria Pharmaceutical Co., Ltd. Quarterly Results
| Line Item | Jun 2026 | Jun 2025 |
|---|---|---|
| EPS | 19.6 | 24.8 |
Zeria Pharmaceutical Co., Ltd. Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 89,159,262,000.0 | 87,311,137,000.0 | 75,725,075,000.0 | 68,383,227,000.0 | — |
| Net Profit | 8,454,544,000.0 | 9,936,323,000.0 | 7,731,262,000.0 | 6,195,865,000.0 | — |
| EPS | 191.8 | 225.4 | 175.4 | 140.3 | — |
Zeria Pharmaceutical Co., Ltd. Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Total Assets | 179,697,949,000.0 | 159,171,596,000.0 | 150,533,593,000.0 | 135,034,536,000.0 |
| Total Liabilities | 71,093,159,000.0 | 69,374,569,000.0 | 70,704,801,000.0 | 69,353,826,000.0 |
| Total Equity | 108,396,740,000.0 | 89,539,837,000.0 | 79,622,561,000.0 | 65,449,915,000.0 |
Zeria Pharmaceutical Co., Ltd. Assets & Liabilities Breakdown (JPY millions)
What it owns — Mar 2026
Cash & short-term investments 15.4%Receivables 17.5%Inventory 11.6%Fixed assets (tangible) 15.4%Intangible assets 22.0%Long-term investments 5.6%Other assets 12.4%
How it's funded — Mar 2026
Short-term debt 18.8%Long-term debt 2.9%Payables 2.7%Other liabilities 15.1%Shareholders' equity 60.4%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 27,760.0 | 23,592.7 | 20,323.7 | 16,219.1 |
| Receivables | 31,413.4 | 26,742.2 | 21,249.3 | 17,512.9 |
| Inventory | 20,896.8 | 16,433.9 | 14,489.8 | 12,764.2 |
| Fixed assets (tangible) | 27,599.4 | 26,641.4 | 26,517.8 | 24,591.4 |
| Intangible assets | 39,581.8 | 40,361.7 | 43,139.7 | 41,930.7 |
| Long-term investments | 10,112.4 | 8,865.6 | 9,145.2 | 6,849.3 |
| Other assets | 22,334.2 | 16,534.2 | 15,668.1 | 15,167.0 |
| Liabilities & equity | ||||
| Short-term debt | 33,834.2 | 34,298.4 | 38,283.7 | 34,890.5 |
| Long-term debt | 5,269.7 | 6,865.8 | 7,943.8 | 14,541.5 |
| Payables | 4,896.0 | 3,971.5 | 3,273.9 | 1,996.1 |
| Other liabilities | 27,093.2 | 24,238.9 | 21,203.3 | 17,925.8 |
| Shareholders' equity | 108,604.8 | 89,797.0 | 79,828.8 | 65,680.7 |
| Net tangible assets | 68,815.0 | 49,178.2 | 36,482.9 | 23,519.2 |
Zeria Pharmaceutical Co., Ltd. Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 9,955,621,000.0 | 12,922,046,000.0 | 12,183,609,000.0 | 13,157,415,000.0 | — |
| Investing Activities | -2,701,776,000.0 | -1,050,885,000.0 | -3,952,373,000.0 | -2,574,517,000.0 | — |
| Financing Activities | -5,933,023,000.0 | -7,756,699,000.0 | -8,124,090,000.0 | -7,415,068,000.0 | — |